AustCancer subsidiary signs distribution deal

By Renate Krelle
Tuesday, 06 July, 2004

ACT US, the US subsidiary of oncology specialist Australian Cancer Technology ("AustCancer") (ASX: ACU) has signed a distribution deal for its revisys range of nutritional supplements.

Under the deal, wholesale drug cooperative Rochester Drug Cooperative will stock revisys in more than eight hundred community retail pharmacies long-term care pharmacies and home health care stores in New York State, Pennsylvania and New Jersey.

Related News

Shingles vaccine may reduce risk of heart attack and stroke 

Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...

Perioperative trial offers insights into brain cancer treatment

Victorian brain cancer researchers have used an innovative process to learn how a new drug...

New molecular mechanism found for depression

Depression may not only result from simple neuronal damage but can also arise from the...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd